New US Study Links Fish Oil Supplements to Potential Brain Risks in Older Adults

Shocking Revelations from MUSC Research on Fish Oil and Brain Health

A groundbreaking study from the Medical University of South Carolina (MUSC) has turned heads in the neuroscience community by suggesting that fish oil supplements, long hailed as a boon for brain health, might pose risks in certain contexts. Published in Cell Reports in April 2026, the research led by neuroscientist Onder Albayram, Ph.D., reveals how eicosapentaenoic acid (EPA)—one of the primary omega-3 fatty acids in fish oil—could impair brain repair mechanisms following repeated mild traumatic brain injuries (TBIs). This finding challenges decades of promotional claims and underscores the need for nuanced approaches to supplementation, particularly among older adults who may have accumulated subtle brain insults over time.

The study doesn't claim fish oil causes cognitive decline in healthy individuals but highlights vulnerability in brains already stressed by injury. For academics and researchers tracking neurodegeneration, this opens new avenues for investigating context-dependent effects of popular nutraceuticals.

The Rise of Omega-3 Supplements in American Diets

Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been staples in the American supplement market since the 1990s. Derived mainly from fish oil, these polyunsaturated fats are praised for reducing inflammation, supporting heart health, and potentially safeguarding cognition. The global market for omega-3 supplements exceeded $5 billion in 2025, with the US accounting for nearly 40% of sales, according to industry reports.

Public health campaigns and endorsements from organizations like the American Heart Association have fueled consumption, especially among those over 65, where cognitive concerns loom large. Nearly 30% of US adults over 60 take omega-3 supplements daily, per National Health and Nutrition Examination Survey data. Yet, while dietary sources like fatty fish consistently show benefits in epidemiological studies, supplement trials have yielded mixed results, prompting scrutiny from university labs nationwide.

Delving into the MUSC Study: Methods and Design

MUSC researchers employed a multi-model approach to probe fish oil's long-term effects. First, they subjected mice to repeated mild head impacts mimicking sub-concussive events common in sports or aging falls. These animals received standard fish oil supplementation over months, tracking neurological performance, spatial learning via maze tests, vascular stability, and molecular repair signals.

Human brain microvascular endothelial cells were cultured under injury-mimicking conditions to test EPA's direct impact on angiogenesis (new blood vessel formation) and barrier integrity. Postmortem analysis of brains from chronic traumatic encephalopathy (CTE) patients—often former athletes—examined fatty acid profiles, gene expression, and tau protein accumulation around vessels.

This rigorous design, spanning animal models, cellular assays, and human pathology, positions the study as a pivotal contribution from US academic medicine.

Key Findings: EPA's Role in Neurovascular Instability

The results were striking: mice on fish oil showed poorer spatial learning and neurological scores compared to controls. Brains exhibited unstable blood vessels, disrupted repair gene expression, and perivascular tauopathy—a hallmark of neurodegeneration where tau proteins aggregate near vessels, impeding clearance and fueling decline.

EPA, accumulating more than DHA in injured cortices, reprogrammed metabolism, reducing genes for extracellular matrix organization and endothelial integrity. In human cells, EPA weakened angiogenic networks and barrier function. CTE tissues mirrored this: disrupted lipid handling and vascular pathways correlated with higher EPA.

MUSC's press release quotes Albayram: "Biology is context-dependent. Long-term supplementation revealed delayed vulnerability in sensitive brains."

EPA vs. DHA: Why One Omega-3 Might Harm While the Other Helps

Not all omega-3s are equal. DHA integrates deeply into neuronal membranes, supporting structure and signaling—benefits seen in prior trials for APOE4 carriers at Alzheimer's risk. EPA, however, prioritizes inflammation modulation peripherally and less so in the brain, where it may disrupt post-injury repair.

The study notes EPA's preferential buildup in injured areas alters lipid metabolism, mimicking features of tau-linked diseases like CTE. This dichotomy explains why fish-heavy diets (rich in both) protect, but EPA-dominant supplements falter in vulnerable states. University nutritionists now advocate DHA-focused formulations for brain health research.

Implications for Older Adults and Brain Injury Survivors

Over 80 million US adults have experienced TBIs, many mild and repetitive from falls, sports, or military service. Older adults, with cumulative micro-injuries, represent a growing cohort. The study warns supplements might exacerbate risks in this group, potentially accelerating decline via tauopathy.

No evidence suggests harm in healthy brains, but for those with vascular risks or injury history, caution is urged. This resonates in higher education, where neuroscience departments study aging populations amid rising supplement use.

Conflicting Evidence: A Nuanced Research Landscape

Not all data damns fish oil. A June 2026 analysis of ADNI data (Journal of Prevention of Alzheimer's Disease) linked general omega-3 use to faster decline via synaptic hypometabolism. Yet, Framingham and other cohorts show blood omega-3s predict slower atrophy.

Dose, form (food vs. pill), genetics (APOE4), and baseline health matter. OHSU's 2024 trial found fish oil slowed neuronal breakdown in at-risk elderly. Meta-analyses indicate modest benefits for mild impairment but null or negative for advanced dementia.

US universities like UC and MUSC lead reconciling these via precision trials.

Expert Voices from US Academia

Dr. Albayram emphasizes personalization: "We can't assume uniform benefits." Peers at Johns Hopkins note EPA's vascular effects warrant subtype-specific advice. Harvard's nutrition experts call for RCTs stratifying by injury history.

In higher ed, this fuels debates on translational research funding, with NIH prioritizing context-specific nutraceutical studies.

Practical Advice: Food Sources, Dosage, and When to Consult

Researchers recommend fatty fish (salmon, mackerel) twice weekly for balanced EPA/DHA over high-EPA pills. Limit supplements to 1g/day unless prescribed; monitor if TBI history exists.

Older adults should discuss with physicians, especially alongside statins or blood thinners. Emerging DHA-only options from university spin-offs offer promise.

University Research Driving Nutrition Science Forward

MUSC's work exemplifies US higher ed's role in challenging dogma. Funded by NIH, it highlights interdisciplinary neuroscience—spanning trauma, metabolism, pathology. Similar probes at OHSU, UC probe subtypes.

This advances careers in clinical research, with demand for experts in neurodegeneration rising 15% per BLS projections.

Future Directions: Precision Nutrition and Clinical Trials

Ongoing NIH trials test DHA isolates post-TBI. Genomics will tailor advice—APOE4 may benefit differently. Universities gear for longitudinal studies tracking supplement-brain interactions in aging cohorts.

By 2030, AI-driven meta-analyses from ADNI-like databases may clarify thresholds, revolutionizing preventive neuroscience.

Photo by Mark Koenov on Unsplash

Balancing Hype with Science in Brain Health

The MUSC study reminds us supplements aren't panaceas. While omega-3s hold promise from dietary sources, vulnerability contexts demand caution. US academia's rigorous scrutiny ensures evidence-based guidance, protecting older adults amid cognitive epidemic projections (16 million with Alzheimer's by 2050).

Stay informed via university-led research—key to navigating nutrition's complexities.